{
  "Cancer Histology Type (Ov)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Steven,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        1250, 
        1264
      ]
    }
  ], 
  "Clinical History Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Steven,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        1633, 
        1656
      ]
    }
  ], 
  "Final Diagnosis Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Steven,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        1157, 
        1184
      ]
    }
  ], 
  "Laterality (Ov)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        1117, 
        1122
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        1186, 
        1191
      ]
    }
  ], 
  "Macroscopic/Gross Description Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Steven,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        551, 
        580
      ]
    }
  ], 
  "Microscopic Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Steven,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        1356, 
        1391
      ]
    }
  ], 
  "Nature of Specimen Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Steven,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        1089, 
        1115
      ]
    }
  ], 
  "Neoplasm Behaviour (Ov)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        1239, 
        1249
      ]
    }
  ], 
  "Primary Origin of Neoplasm (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        1281, 
        1297
      ]
    }
  ], 
  "__text": "MSH|^~\\&|PathSys|Associated Pathologists, LLC d/b/a PathGroup^44D1084007^CLIA|eMARCPlus|TN Cancer Registry|20170919125831||ORU^R01^ORU_R01|201709191258310001|P|2.5.1|TN||||||||VOL_V_40_ORU_R01-CCR1^NAACCR_CP\nOBR|1||17-55-004466^PathSys^44D1084007^CLIA|11529-5^SURGICAL PATH REPORT^LN|||20170809000000|||||||20170809000000|&Core Biopsy Mass|1285654210^^^^^^MD^^CMS^D^^^NPI||||||20170810000000|||F||||||C77.5^Secondary and unspecified malignant neoplasm of intrapelvic lymph nodes^I10~C61^Malignant neoplasm of prostate^I10|1114037611&&&&&&&&CMS\n\n\n\n\n\n\n\nPath report.gross description\n\nThe patient is \"\" identified by requisition and specimen container label. Received fresh for touch prep adequacy determination in a container labeled with the patient's name and identified per the accompanying pathology requisition as \"CT guided lymph node biopsy right external iliac\" are approximately ten, less than 0.1 to 1.2 cm long cores of tan and red-brown tissue each with a diameter of less than 0.1 cm. Following touch preparation, the tissue is submitted in its entirety in cassette 1A. (JDM)\n\n\nPath report.site of origin\n\nRight external iliac lymph node cores\n\n\nPath report.final diagnosis\n\nRight external iliac lymph node, CT-guided biopsy:   Metastatic adenocarcinoma consistent with prostatic origin.   Immunoreactivity profile: Positive for p501 and PSA.\n\n\nPath report.microscopic examination\n\nSections show abundant lymphoid tissue focally involved by gland forming tumor morphologically consistent with prostatic origin, and confirmed by the prostatic markers p501 and prostate specific antigen. The controls react appropriately.\n\n\nPath report.relevant Hx\n\nHistory - Prostate cancer\n\n\n"
}